SARS‐CoV‐2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID‐19 vaccination
In Denmark, vaccination against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS‐CoV‐2) has been with the Pfizer‐BioNTech (BTN162b2) or the Moderna (mRNA‐1273) mRNA vaccines. Patients with chronic hepatitis C virus (HCV) infection followed in our clinic received mRNA vaccinations according to...
Gespeichert in:
Veröffentlicht in: | APMIS : acta pathologica, microbiologica et immunologica Scandinavica microbiologica et immunologica Scandinavica, 2023-03, Vol.131 (3), p.128-132 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In Denmark, vaccination against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS‐CoV‐2) has been with the Pfizer‐BioNTech (BTN162b2) or the Moderna (mRNA‐1273) mRNA vaccines. Patients with chronic hepatitis C virus (HCV) infection followed in our clinic received mRNA vaccinations according to the Danish roll‐out vaccination plan. To monitor HCV infection, RNA was extracted from patient plasma and RNA sequencing was performed on the Illumina platform. In 10 of 108 HCV patient samples, full‐length or traces of SARS‐CoV‐2 spike mRNA vaccine sequences were found in blood up to 28 days after COVID‐19 vaccination. Detection of mRNA vaccine sequences in blood after vaccination adds important knowledge regarding this technology and should lead to further research into the design of lipid‐nanoparticles and the half‐life of these and mRNA vaccines in humans. |
---|---|
ISSN: | 0903-4641 1600-0463 |
DOI: | 10.1111/apm.13294 |